DCM
CORT icon

Delpha Capital Management’s Corcept Therapeutics CORT Stock Holding History

Delpha Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,407
Closed -$25K – 349
2017
Q4 		$25K Buy
+1,407
New +$25.5K 0.03% 650

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Delpha Capital Management's CORT Position: Q1 2018 in Review

Delpha Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2018, closing a stake of 1,407 shares — an estimated $25K sold.

Delpha Capital Management first reported a position in CORT in Q4 2017 and held it in 1 quarter. The position peaked at $25K in Q4 2017. 212 funds tracked by Wall St. Rank hold CORT as of Q1 2018.

  • Delpha Capital Management reported no remaining Corcept Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 1,407 Corcept Therapeutics shares in Q1 2018, an estimated $25K.
  • Delpha Capital Management first reported a position in Corcept Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Corcept Therapeutics position peaked at $25K in Q4 2017.
  • 212 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.